Pancreatic cancer: The RAS paradigm shift
by Samuel P. Soff, Eileen M. O’Reilly Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. Recent advances in RAS targeting with small molecules are redefining therapeutic paradigms. Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic…
We haven't written up this one. PLOS Medicine has the full story — the link below goes straight to it.
